Axsome Therapeutics
AXSM
$233.80
-6.09%
Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders with limited treatment options. It distinguishes itself through a pipeline targeting major CNS conditions, including AXS-05 for depression and AXS-07 for migraine, positioning it as a potential leader in CNS innovation. The current investor narrative centers on the company's rapid revenue growth from recently launched products, with the stock surging over 135% in the past year amid strong commercial execution and pipeline progress. Recent analyst actions and news highlight optimism around its growth trajectory, though profitability remains a key debate as the company continues to invest heavily in R&D and commercialization.…
AXSM
Axsome Therapeutics
$233.80
Related headlines
Investment Opinion: Should I buy AXSM Today?
Rating: Buy. Thesis: Axsome's rapid revenue growth (65% YoY), improving margins, and compelling forward valuation (forward PS 2.4x) position it for significant upside as it approaches profitability, supported by a unanimous analyst Buy consensus.
Supporting Evidence: The company's Q4 2025 revenue of $196M grew 65% YoY, with gross margins of 93.7% providing operating leverage. Net loss narrowed from $74.9M to $28.6M year-over-year, and operating margin improved from -61.1% to -15.0%. The forward PS ratio of 2.4x (based on estimated revenue of $3.79B) is well below the biotech industry average of 5-10x, suggesting undervaluation relative to future revenue. All 8 analysts rate the stock Buy, with average EPS estimate of $32.53, implying strong profitability ahead.
Risks & Conditions: Key risks include failure to sustain revenue growth, unexpected increases in operating expenses, and pipeline setbacks. The rating would be downgraded to Hold if revenue growth decelerates below 30% YoY or if cash burn accelerates. It would be upgraded if the company achieves positive net income earlier than expected. Overall, the stock appears undervalued on a forward PS basis relative to its growth trajectory, though trailing valuation is elevated.
Sign up to view all
AXSM 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Axsome's rapid revenue growth and improving margins are strong indicators of a successful commercial transition. The forward valuation is attractive relative to the biotech sector, and analyst sentiment is uniformly positive. However, the company remains unprofitable, and the high short interest introduces uncertainty. The key factor to watch is whether revenue growth can sustain above 50% and whether operating margins continue to improve. If these trends hold, the stock has significant upside; if they falter, the downside could be substantial. The stance would be upgraded to high confidence if the company achieves positive net income in the next two quarters.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axsome Therapeutics's 12-month outlook, with a consensus price target around $303.94 and implied upside of +30.0% versus the current price.
Average Target
$303.94
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$187 - $304
Analyst target range
Axsome is covered by 8 analysts, with a consensus leaning bullish. All recent ratings from firms like Guggenheim, Wells Fargo, RBC Capital, UBS, Needham, Jefferies, and Leerink Partners are Buy or Outperform, with no Sell ratings. The average estimated EPS for the next fiscal year is $32.53, with a low of $25.57 and high of $40.30. The average estimated revenue is $3.79 billion, with a range of $3.17 billion to $4.49 billion. Based on the current price of $244.31, the implied upside to the average target (if we assume a forward PE of 41.4x on average EPS) would be significant, but since the company is not yet profitable on a GAAP basis, the target price is not directly calculable from the data. However, the strong buy consensus and upward revisions indicate analyst confidence. The target range for EPS estimates ($25.57 to $40.30) implies a wide spread, reflecting high uncertainty about the pace of profitability. The high end assumes rapid margin expansion and continued revenue growth, while the low end may factor in competitive pressures or slower adoption. The recent pattern of analyst upgrades and reiterations (e.g., Guggenheim, RBC Capital) suggests positive sentiment, but the wide EPS range indicates that the path to profitability remains a key variable.
Bulls vs Bears: AXSM Investment Factors
Axsome presents a compelling growth story with rapid revenue expansion (65% YoY), improving margins, and a strong analyst consensus. The bull case is supported by high gross margins, a path to profitability, and a forward PS ratio that appears attractive relative to industry peers. However, the bear case highlights persistent losses, negative free cash flow, high leverage, and a premium trailing valuation that leaves little room for error. The single most important tension is whether the company can sustain its revenue growth trajectory and achieve profitability before its cash runway diminishes. If growth accelerates and margins improve, the stock could re-rate higher; if growth stalls or expenses outpace revenue, the downside could be significant.
Bullish
- Rapid Revenue Growth Trajectory: Revenue grew 65% YoY in Q4 2025 to $196M, with sequential acceleration from $87.2M in Q2 2024. This consistent growth is driven by product sales ($194.7M), indicating strong commercial execution.
- Improving Profitability Metrics: Net loss narrowed from $74.9M in Q4 2024 to $28.6M in Q4 2025, while operating margin improved from -61.1% to -15.0%. The trajectory suggests a path to breakeven as revenue scales.
- High Gross Margin Business Model: Gross margin of 93.7% in Q4 2025 is typical for biotech products, allowing significant operating leverage as revenue grows. This supports the potential for strong incremental profitability.
- Strong Analyst Consensus: All 8 analysts rate the stock Buy/Outperform, with average EPS estimate of $32.53 for next fiscal year. The unanimous bullish sentiment reflects confidence in the pipeline and commercial prospects.
Bearish
- Negative Earnings and Cash Burn: Despite revenue growth, the company remains unprofitable with a TTM net loss and negative free cash flow of -$93.8M. High debt-to-equity of 2.73x and negative ROE of -207.5% indicate financial risk.
- Premium Trailing Valuation: Trailing PS ratio of 14.2x is above the biotech industry average, implying high expectations. If revenue growth decelerates, the stock could face multiple compression.
- High Short Interest: Short ratio of 4.99 days suggests significant bearish sentiment. A high short interest can lead to volatility, and any negative news could trigger sharp declines.
- Execution Risk on Pipeline: As a clinical-stage company, Axsome's future depends on successful development and commercialization of pipeline products like AXS-05 and AXS-07. Any regulatory setbacks or competitive pressures could derail growth.
AXSM Technical Analysis
Axsome is in a sustained uptrend, with the stock price up 135.1% over the past year. As of July 2, 2026, the stock closed at $244.31, which is 93.9% of its 52-week range of $96.09 to $260.19. Trading near the top of the range suggests strong momentum and bullish sentiment, but also implies the stock may be overextended in the short term. Short-term momentum is accelerating, with a 1-month price change of +10.0% and a 3-month change of +45.0%, both significantly outpacing the S&P 500's -1.3% and +13.6% over the same periods. The 1-month relative strength of +11.2% indicates the stock is gaining against the market, while the 3-month relative strength of +31.4% confirms a strong upward trend. This acceleration suggests the uptrend is intact and may have further room to run, though the rapid pace could lead to short-term pullbacks. Key support is at the 52-week low of $96.09, while resistance is at the 52-week high of $260.19. A breakout above $260.19 would signal a continuation of the uptrend and likely attract further buying. Conversely, a breakdown below recent support near $230 could indicate a short-term correction. The stock's beta of 0.60 suggests it is less volatile than the overall market, which may appeal to risk-averse investors but also means it may underperform during market rallies.
Beta
0.60
0.60x market volatility
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
$96-$260
Price range past year
Annual Return
+111.1%
Cumulative gain past year
| Period | AXSM Return | S&P 500 |
|---|---|---|
| 1m | -5.1% | +4.1% |
| 3m | +31.3% | +11.1% |
| 6m | +38.0% | +8.8% |
| 1y | +111.1% | +20.6% |
| ytd | +30.8% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXSM Fundamental Analysis
Axsome's revenue is growing rapidly, with Q4 2025 revenue of $196.0 million, up 65.0% year-over-year from $118.8 million in Q4 2024. The multi-quarter trend shows accelerating growth: revenue rose from $87.2 million in Q2 2024 to $121.5 million in Q1 2025, $150.0 million in Q2 2025, $171.0 million in Q3 2025, and $196.0 million in Q4 2025. This consistent sequential growth is driven by product sales, which accounted for $194.7 million of Q4 2025 revenue. The strong top-line expansion supports the investment case for a company transitioning from clinical-stage to commercial-stage, though the pace of growth will need to be sustained to justify the current valuation. The company remains unprofitable, with a net loss of $28.6 million in Q4 2025, though this loss narrowed significantly from a net loss of $74.9 million in Q4 2024. Gross margin is very high at 93.7% in Q4 2025, typical for biotech with high-margin products. However, operating margin was -15.0% in Q4 2025, improving from -61.1% in Q4 2024, indicating that operating expenses are growing slower than revenue. The net margin improved to -14.6% from -63.1% a year ago, showing a clear trajectory toward profitability. Axsome's balance sheet shows a current ratio of 1.55, indicating adequate liquidity, but debt-to-equity is high at 2.73, reflecting significant leverage. Free cash flow was negative $19.0 million in Q4 2025, though it improved from negative $26.2 million in Q4 2024. The company had $322.9 million in cash at the end of Q4 2025, providing a cushion for ongoing operations. ROE is deeply negative at -207.5%, reflecting the net losses and high equity base, but this is typical for a growth-stage biotech.
Quarterly Revenue
$195999000.0B
2025-12
Revenue YoY Growth
+65.03%
YoY Comparison
Gross Margin
93.71%
Latest Quarter
Free Cash Flow
$-93814000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXSM Overvalued?
Since Axsome has negative net income (TTM net loss), the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio is 14.2x, while the forward PS ratio (based on estimated revenue of $3.79 billion) is approximately 2.4x, implying the market expects massive revenue growth. The gap between trailing and forward PS suggests aggressive growth expectations are priced in. Compared to the biotechnology industry average PS ratio (which is typically around 5-10x for profitable companies), Axsome's trailing PS of 14.2x is at a premium. However, its forward PS of 2.4x is below the industry average, reflecting the anticipated revenue surge. The premium on trailing sales may be justified by the company's high gross margins (93.7%) and rapid revenue growth (65% YoY). Historically, Axsome's PS ratio has ranged from near 0 (pre-revenue) to over 100x. The current trailing PS of 14.2x is near the lower end of its historical range, suggesting that while the stock has appreciated, the multiple has compressed as revenue has grown. This could indicate that the market is pricing in a more mature growth trajectory, but the forward PS suggests optimism about future expansion.
PE
-49.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -81x~-9x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Axsome's primary financial risk is its persistent unprofitability and negative free cash flow. Despite revenue growing 65% YoY to $196M in Q4 2025, the company still posted a net loss of $28.6M and negative free cash flow of $19M in that quarter. The debt-to-equity ratio of 2.73x indicates significant leverage, and the negative ROE of -207.5% reflects the drag from losses on equity. With $322.9M in cash, the company has a cushion, but continued cash burn could necessitate dilutive financing if profitability is delayed. The operating margin of -15.0%, while improving, shows that operating expenses are still outpacing revenue growth, and any slowdown in revenue could widen losses.
Market & Competitive Risks: The stock trades at a trailing PS of 14.2x, a premium to the biotech industry average, making it vulnerable to valuation compression if growth disappoints. The beta of 0.60 suggests lower market correlation, but the stock's 135% surge over the past year implies high momentum that could reverse. The short ratio of 4.99 days indicates significant bearish positioning, which could amplify downside on negative news. Competitive risks include potential new entrants in CNS disorders and pricing pressures. Recent news highlights optimism, but the wide EPS estimate range ($25.57-$40.30) underscores uncertainty about the pace of profitability.
Worst-Case Scenario: In a worst-case scenario, a clinical trial failure or regulatory setback for a key pipeline product (e.g., AXS-05) could halt revenue growth and trigger a sharp sell-off. Combined with high debt and cash burn, the stock could fall to its 52-week low of $96.09, representing a 60.7% decline from the current price of $244.31. Historical max drawdown of -18.5% suggests the stock is volatile, but a fundamental catalyst could drive losses far beyond that. Investors could lose up to 60% of their investment in this adverse scenario.
FAQ
The key risks are: 1) Financial risk: The company is unprofitable with negative free cash flow (-$93.8M TTM) and high debt-to-equity of 2.73x, which could lead to dilution if cash runs out. 2) Execution risk: As a clinical-stage biotech, pipeline failures (e.g., AXS-05 or AXS-07) could halt growth. 3) Valuation risk: The trailing PS of 14.2x is above industry average, leaving the stock vulnerable to multiple compression if growth slows. 4) Market risk: The short ratio of 4.99 days indicates bearish sentiment, and the stock's 135% one-year gain could lead to profit-taking. The most severe risk is a clinical trial failure, which could cause a 60%+ decline toward the 52-week low of $96.09.
The 12-month forecast is bullish with a base case target range of $250-$300 (50% probability), assuming 50-65% revenue growth and gradual margin improvement. The bull case (30% probability) targets $300-$350, driven by accelerated growth and early profitability. The bear case (20% probability) sees the stock falling to $150-$200 if growth decelerates or pipeline issues arise. The most likely scenario is the base case, where the stock trades modestly higher from the current $244.31. Key assumptions include sustained revenue growth above 50% and continued operating margin improvement. The wide EPS estimate range ($25.57-$40.30) highlights uncertainty, but the consensus is positive.
Axsome's valuation is mixed. On a trailing basis, the PS ratio of 14.2x is above the biotech industry average of 5-10x, suggesting the market is paying a premium for past performance. However, the forward PS ratio of 2.4x (based on estimated revenue of $3.79B) is well below the industry average, indicating the stock may be undervalued relative to future revenue. The PEG ratio of 1.29x, based on expected EPS growth, is reasonable for a high-growth company. Historically, the PS ratio has ranged from near 0 to over 100x, so the current level is moderate. Overall, the market is pricing in aggressive growth expectations, but if those expectations are met, the stock is undervalued on a forward basis.
Axsome presents a compelling risk/reward for growth investors. With revenue growing 65% YoY to $196M in Q4 2025 and a forward PS ratio of 2.4x (below the biotech average of 5-10x), the stock offers significant upside if growth continues. However, the company is still unprofitable with negative free cash flow, and the trailing PS of 14.2x is elevated. The unanimous analyst Buy consensus and average EPS estimate of $32.53 suggest strong future profitability. The biggest downside risk is a growth deceleration or pipeline failure, which could send the stock to the 52-week low of $96.09. For investors with a high risk tolerance and a long-term horizon (3-5 years), AXSM is a good buy; for conservative investors, it may be too speculative.
Axsome is better suited for long-term investment (3-5 years) due to its clinical-stage nature and high volatility. The stock's beta of 0.60 is below the market, but its 135% one-year gain and 18.5% max drawdown indicate significant short-term swings. The company is not yet profitable and does not pay a dividend, so it is not suitable for income investors. Short-term trading could be profitable given the momentum, but the high short ratio (4.99 days) and wide analyst estimates create uncertainty. For long-term investors, the thesis rests on successful commercialization and profitability, which could take several years. A minimum holding period of 3 years is recommended to allow the pipeline to mature and revenue to scale.